Tactical Therapeutics Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
4
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 28, 2027The maintenance fee for Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate (US 9,089,570) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 1 fee due Feb 13, 2027The maintenance fee for Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate (US 10,378,059) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,420,658 | Use of Carboxyamidotriazole (CAI) orotate in macular degeneration In force · From the USPTO record | In force | From the USPTO record | |
| US 7,750,018 | Use of carboxiamidotriazole (CAI) orotate in macular degeneration In force · From the USPTO record | In force | From the USPTO record | |
| US 8,377,973 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations In force · From the USPTO record | In force | From the USPTO record | |
| US 8,877,785 | Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate In force · From the USPTO record | In force | From the USPTO record | |
| US 8,912,223 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazoles orotate formulations In force · From the USPTO record | In force | From the USPTO record | |
| US 9,089,570 | Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate In force · From the USPTO record | In force | From the USPTO record | |
| US 10,378,059 | Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate In force · From the USPTO record | In force | From the USPTO record | |
| US 11,318,118 | Methods and compositions for treating SARS-CoV-2 infection using carboxyamidotriazole orotate In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 8: 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned